Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus Irinotecan in Advanced Gastric Cancer
NCT00209638Phase 2Completed
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- May 2000
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tegafur and irinotecan in gastric cancer (GC), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoint: Objective Tumor Response. Started May 2000; status: completed.
02
Drugs
tegafuririnotecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00209638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209638.